cme
Psychopharmacological Treatment in Older People: Avoiding Drug Interactions and Polypharmacy
Dtsch Arztebl Int 2019; 116: 508-18. DOI: 10.3238/arztebl.2019.0508
;
| 1. | Statistisches Bundesamt: Bevölkerung Deutschlands bis 2060. 2. koordinierte Bevölkerung, Familien, Lebensformen. www.destatis.de/DE/Publikationen/StatistischesJahrbuch/StatistischesJahrbuch.html (last accessed on 06 June 2019). |
| 2. | Van der Akker M, Buntinx F, Knottnerus A: Comorbidity or multimorbidity: what’s in a name? A review of the literature. Eur J Gen Pract 1996; 2: 65–70 CrossRef |
| 3. | Van der Hooft CS, Dieleman JP, Siemes C, et al.: Adverse drug reaction-related hospitalisations: a population-based cohort study. Pharmacoepidemiol Drug Saf 2008; 17: 365–71 CrossRef MEDLINE |
| 4. | Pirmohamed M, James S, Meakin S, et al.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15–9 CrossRef CrossRef MEDLINE PubMed Central |
| 5. | Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM: Frequency of and risk factors for preventable medication-related hospital admis sions in the Netherlands. Arch Intern Med 2008; 168: 1890–6. |
| 6. | Stang AS, Wingert AS, Hartling L, Plint AC: Adverse events related to emergency department care: a systematic review. PLoS One 2013; 8: e74214 CrossRef MEDLINE PubMed Central |
| 7. | Onder G, Liperoti R, Fialova D, et al.: Polypharmacy in nursing home in Europe: results from the SHELTER study. Gerontol A Biol Sci Med Sci 2012; 67: 698–704 CrossRef MEDLINE |
| 8. | Holt S, Schmiedl S, Thürmann PA: Potentially inappropriate medications in the elderly – The PRISCUS List. Dtsch Arztebl Int 2010; 107: 543–51 CrossRef MEDLINE PubMed Central |
| 9. | Berdot S, Bertrand M, Dartigues JF, et al.: Inappropriate medication use and risk of falls—a prospective study in a large community-dwelling elderly cohort. BMC Geriatrics 2009; 9: 30 CrossRef MEDLINE PubMed Central |
| 10. | Dumbreck S, Flynn A, Nairn M, et al.: Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ 2015; 350: h949 CrossRef MEDLINE PubMed Central |
| 11. | Moßhammer D, Haumann H, Mörike K, Joos S: Polypharmacy—an upward trend with unpredictable effects. Dtsch Arztebl Int 2016; 113: 627–33 CrossRef MEDLINE PubMed Central |
| 12. | Bertsche T, Pfaff J, Schiller P, et al.: Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system. Intensive Care Med 2010; 36: 665–72 CrossRef MEDLINE |
| 13. | Mutschler E, Geisslinger G, Kroemer HK, Menzel S, Ruth P: Arzneimittelwirkungen: Pharmakologie – Klinische Pharmakologie – Toxikologie. 10. Auflage. Stuttgart: Wissenschaftliche Verlagsgesellschaft 2012. |
| 14. | Bauer JM, Wirth R, Volker D, Sieber C: Malnutrition, Sarkopenie und Kachexie im Alter – Von der Pathophysiologie zur Therapie. Dtsch Med Wschr 2008; 133: 305–10 CrossRef MEDLINE |
| 15. | Müller WE: Sedativa als Beispiel für die Besonderheiten der Psychopharmakotherapie im Alter. In: Förstl H (ed.): Lehrbuch Gerontopsychiatrie. Stuttgart: Thieme Verlag 2002; 220–6. |
| 16. | Berthold H, Steinhagen-Thiessen E: Arzneimitteltherapie im Alter – Wo liegen die Probleme? Was soll man tun, was muss man lassen? Internist 2009; 50: 1415–24 CrossRef MEDLINE |
| 17. | Jelliffe RW: Creatinine clearance: bedside estimate. Ann Intern Med 1973; 79: 604–5 CrossRef MEDLINE |
| 18. | Briciu C, Neag M, Muntean D, et al.: A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. J Clin Pharm Ther 2014; 39: 535–40 CrossRef MEDLINE |
| 19. | Benkert O, Hippius H: Kompendium der Psychiatrischen Pharmakotherapie. 12. Auflage. Berlin, Heidelberg: Springer Verlag 2018. |
| 20. | Benkert O: Pocket Guide Psychopharmaka von A bis Z. 4th edition. Berlin, Heidelberg: Springer Verlag 2017 CrossRef |
| 21. | Poulsen L, Arendt-Nielsen L, Brøsen K, Brøsen K, Sindrup SH: The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60: 636–44 CrossRef |
| 22. | Petri H: CYP450-Wechselwirkungen: Interaktionen der SSRI-Antidepressiva. Dtsch Arztebl (Suppl. Perspektiven in der Neurologie) 2015; 112: 33–4. |
| 23. | Hewer W, Eckermann G: Bedenkliche Arzneimittelkombinationen bei geriatrischen Patienten. Psychopharmakotherapie 2011; 18: 10–17. |
| 24. | Flockhart DA, Drici MD, Kerbusch T, et al.: Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with tourette syndrome. J Clin Psychopharmacol 2000; 20: 317–24 CrossRef MEDLINE |
| 25. | Etheridge AS, Black SR, Pantel PR, So J, Mathews JM: An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldseal, ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 2007; 73: 731–41 CrossRef MEDLINE |
| 26. | Petri H: Arzneimitteltherapiesicherheit: Das Interaktionspotenzial konventioneller Zytostatika. Dtsch Arztebl 2017; 114 (Suppl. Perspektiven in der Onkologie): 19–21 VOLLTEXT |
| 27. | Ekhart C, Rodenhuis S, Beijnen JH, Huitema AD: Carbamazepine induces bioactivation of cyclophosphamide and thiotepa. Cancer Chemother Pharmacol 2009; 63: 543–7 CrossRefMEDLINE |
| 28. | Hu Z, Yang X, Ho PC, Chan SY, et al.: Herb-drug interactions: a literature review. Drugs 2005; 65: 1239–82 CrossRef MEDLINE |
| 29. | Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD: The effects of St John´s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70: 317–26 CrossRef |
| 30. | Hellum BH, Nilsen OG: In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol 2008; 102: 466–75 CrossRef MEDLINE |
| 31. | Lin JH: CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 2006; 23: 1089–116 CrossRef MEDLINE |
| 32. | Flockhart DA: Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine 2007. https://drug-interactions.medicine.iu.edu/main-table.aspx (last accessed on 6 June 2019). |
| 33. | Unger M: Pharmacokinetic drug interactions involving ginkgo biloba. Drug Metab Rev 2013; 45: 353–85 CrossRef MEDLINE |
| 34. | Hakooz N, Hamdan I: Effects of dietary broccoli on human in vivo caffeine metabolism: a pilot study on a group of Jordanian volunteers. Curr Drug Metab 2007; 8: 9–15 CrossRef |
| 35. | Lertxundi U, Domingo-Echaburu S, Hernandez R, Peral J, Medrano J: Expertbased drug lists to measure anticholinergic burden: similar names, different results. Psychogeriatrics 2013; 13: 17–24 CrossRef MEDLINE |
| 36. | Kratz T: The diagnosis and treatment of behavioral disorders in dementia. Dtsch Arztebl Int 2017; 114: 447–54 CrossRef MEDLINE PubMed Central |
| 37. | Kratz T, Heinrich M, Schlauß E, Diefenbacher A: Preventing postoperative delirium – a prospective intervention with psychogeriatric liaison on surgical wards in a general hospital. Dtsch Arztebl Int 2015; 112: 289–96 VOLLTEXT |
| 38. | Grandjean EM, Aubry JM: Lithium: updated human knowledge using an evidencebased approach. Part II: clinical pharmacology and therapeutic monitoring. CNS Drugs 2009; 23: 331–49 CrossRef MEDLINE |
| 39. | Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH: Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163: 2716–24 CrossRef MEDLINE |
| 40. | Interaktionsplattform PSIAC.de: www.psiac.de (last accessed on 6 June 2019). |
| e1. | Budnitz D, Lovegrove M, Shehab N, Richards CL: Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365: 2002–12 CrossRef MEDLINE |
| e2. | Dubrall D, Schmid M, Alešik E, Paeschke N, Stingl J, Sachs B: Frequent adverse drug reactions, and medication groups under suspicion – a descriptive analysis based on spontaneous reports to the German Federal Institute for Drugs and Medical Devices from 1978–2016. Dtsch Arztebl Int 2018; 115: 393–400 VOLLTEXT |
| e3. | Schurig AM, Böhme M, Just KS, Scholl C, Dormann H, Plank-Kiegele B, et al.: Adverse drug reactions (ADR) and emergencies – the prevalence of suspected ADR in four emergency departments in Germany. Dtsch Arztebl Int 2018; 115: 251–8 VOLLTEXT |
| e4. | Fradet G, Legac X, Charlois T, Ponge T, Cottin S: Iatrogenic drug-induced diseases, requiring hospitalisation, in patients over 65 years of age. 1-year retrospective study in an internal medicine department. Revue de medecine interne 1996; 17: 456–60 CrossRef |
| e5. | Mühlberg W, Sieber C: Häufige unerwünschte Arzneimittelwirkungen (UAW) und Vergiftungen im Alter. Notfall & Hausarztmedizin (Hausarztmedizin) 2005; 31: 276–81 CrossRef CrossRef |
| e6. | Cascorbi I: Drug interactions—principles, examples and clinical consequences. Dtsch Arztebl Int 2012; 109: 546–56 VOLLTEXT |
| e7. | Haen E: Arzneimittelinteraktionen. Interaktionen zwischen körperfremden Substanzen. Nervenarzt 2014; 85: 417–26 CrossRef MEDLINE |
| e8. | König F, Kaschka W: Interaktionen und Wirkmechanismen ausgewählter Psychopharmaka. 2nd revised edition. Stuttgart: Thieme Verlag 2003 CrossRef |
| e9. | Hansen W: Medizin des Alterns und des alten Menschen. Darmstadt: Schattauer Verlag 2007; 96–7. |
| e10. | Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, et al.: Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010; 340: c693 CrossRef MEDLINE PubMed Central |
| e11. | He N, Edeki T: The inhibitory effect of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther 2004; 11: 206–12 CrossRef |
| e12. | Boyer EW, Shannon M: Current concepts: the serotonin syndrome. New Engl J Med 2005; 352: 1112–20 CrossRef MEDLINE |
| e13. | Wehling M, Burkhardt H: Arzneimitteltherapie für Ältere. Heidelberg, Berlin: Springer Verlag 2016; 242–7 CrossRef |
| e14. | Sterke CS, Ziere G, van Beeck EF, Looman CWN, van der Cammen TJM: Dose-response relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in nursing home residents with dementia. Br J Clin Pharmacol 2012; 73: 812–20 CrossRef MEDLINE PubMed Central |
| e15. | Wenzel-Seifert K, Wittmann M, Haen E: QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int 2011; 108: 687–93 VOLLTEXT |
| e16. | Voigt N, Ort K, Sossalla S: Arzneimittelinteraktionen, die man kennen muss. Dtsch Med Wochenschr 2019; 144: 264–75 CrossRef MEDLINE |
| e17. | Walraven van C, Mamdam MM, Wells PS, et al.: Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. Brit J Med 2001; 323: 655–8 CrossRef MEDLINE PubMed Central |
| e18. | Izzo A, Ernst E: Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001; 61: 2163–75 CrossRef MEDLINE |
| e19. | Müller-Oerlinghausen B: Unerwünschte Wechselwirkungen von Lithiumsalzen mit anderen Arzneimitteln. In: Müller-Oerlinghausen B, Greil W, Berghöfer A (eds): Die Lithiumtherapie. Berlin: Springer Berlin 1997; 446–55 CrossRef |
| e20. | Roose SP, Glassman AH, Giardina EG, Walsh BT, Woodring S, Bigger JT: Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 1987; 44: 273–5 CrossRef |
| e21. | Roose SP, Glassman AH, Giardina EG, Johnson LL, Walsh BT, Woodring S, et al.: Nortriptyline in depressed patients with left ventricular impairment. JAMA 1986; 256: 3253–7 CrossRef CrossRef MEDLINE |
| e22. | Wehling M, Burkhardt H, Kuhn-Thiel A, et al.: VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age and Ageing 2016; 45: 262–7 CrossRef MEDLINE |
| e23. | Universität Heidelberg Forta-Projekt: www.umm.uni-heidelberg.de/klinische-pharmakologie/forschung/forta-projekt-deutsch/ (last accessed on 6 June 2019). |
| e24. | Universitätsklinikum Heidelberg: DOSING. Informationen zur Arzneimittel-Anwendung & -Sicherheit. Interaktionsplattform: https://dosing.de/ (last accessed on 6 June 2019). |
| e25. | CREDIBLEMEDS® – Interaktionsplattform: https://crediblemeds.org/new-drug-list/ (last accessed on 6 June 2019). |
| e26. | Interaktionsplattform MEDIQ.ch: www.mediq.ch/welcome_public (last accessed on 6 June 2019). |
| e27. | Arzneimittelinteraktionen Android-APP: www.ifap.de/mobile-loesungen/arznei-aktuell-fuer-android/ (last accessed on 6 June 2019). |
| e28. | Schwab M, Marx C, Zanger UM, Eichelbaum M, Fischer-Bosch M: Pharmakogenetik der Zytochrom-P-450-Enzyme. Bedeutung für Wirkungen und Nebenwirkungen von Medikamenten. Dtsch Arztebl 2002; 99: A497–504 VOLLTEXT |
| e29. | Sandson NB: Drug interactions casebook: the cytochrome P450 system and beyond. 1st edition. Washington DC: American Psychiatric Publishing 2003. |
| e30. | Greiner C: Cytochrom-P450-Isoenzyme – Teil 2: Substrate, Induktoren und Inhibitoren. Neurotransmitter 2010; 1: 38–40. |
| e31. | Roe CM, Anderson MJ, Spivack B: Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc 2002; 50: 836–42 CrossRef MEDLINE |
| e32. | Reinbold H: Psychogenicum. Biochemie der Psychopharmaka, differenzierter Umgang mit Neuroleptika. Dortmund: PsychologenVerlag PGV 2001. |
| e33. | Möller HJ: Aktuelle Bewertung neuer/atypischer Neuroleptika. Nervenarzt 2000; 71: 329–44 CrossRef |
| e34. | Garfinkel D, Mangin D: Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med 2010; 170: 1648–54 CrossRef MEDLINE |
